ReviewClinical microbiology reviews2019
Tuberculosis Vaccine Development: Progress in Clinical Evaluation.
Review in Clinical microbiology reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 111 citations in OpenAlex.
- Multidimensional analyses reveal modulation of adaptive and innate immune subsets by tuberculosis vaccines.Communications biology · 2020Trial
- Harnessing conserved epitopes and multivalent antigen strategies for vaccine design: Lessons learned and opportunities.Human vaccines & immunotherapeutics · 2026Review
- Construction of a subunit vaccine based on Mycobacterium tuberculosis EsxE and evaluation of its immunogenicity and ex vivo mycobacterial growth inhibitory activity.Archives of microbiology · 2026Article
- HowVaccines · 2026Review
- Bovine Tuberculosis as a Neglected Zoonotic Disease in Mexico and Latin America: Epidemiological Challenges, Diagnostic Insights, and Public Health Implications in Emerging Economies.Veterinary sciences · 2026Review
- Catalysing tuberculosis elimination in Indonesia: Health economic and policy insights from the BPaL regimen.PloS one · 2026Article
- BCG overexpressing Ag85B reprograms host immune response through coordinated transcriptional networks.Frontiers in immunology · 2026Article
- Identification of immune phenotypes and diagnostic biomarkers in active and latent tuberculosis infections.Scientific reports · 2025Article
- Characterizing TLR4 agonist EmT4™ as an anti-Mycobacterium tuberculosis vaccine adjuvant.ImmunoHorizons · 2025Article
- Tuberculosis: An Update for the Clinician.Respirology (Carlton, Vic.) · 2025Review
- Computational epitope profiling and AI-driven protein engineering enable rational design of multi-epitope vaccines againstComputational and structural biotechnology journal · 2025Article
- Designing tuberculosis elimination framework through participatory processes in Ethiopia: Results from stakeholders' discussions.PloS one · 2025Article
- TB vaccine development: monitoring international patent filings to anticipate access challenges.Frontiers in public health · 2025Article
- The frequency of CD38Nature communications · 2024Article
- CD38+ Alveolar macrophages mediate early control of M. tuberculosis proliferation in the lung.Research square · 2024Article
- The whole genome sequence of Polish vaccine strainMicrobiology spectrum · 2024Article
- Optimizing antigen selection for the development of tuberculosis vaccines.Cell insight · 2024Review
- Live Attenuated Vaccines against Tuberculosis: Targeting the Disruption of Genes Encoding the Secretory Proteins of Mycobacteria.Vaccines · 2024Review
- Interleukin-26 expression in tuberculosis disease and its regulatory effect in macrophage polarization and intracellular elimination ofFrontiers in cellular and infection microbiology · 2024Article
- Proteomics study the potential targets for Rifampicin-resistant spinal tuberculosis.Frontiers in pharmacology · 2024Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) is the leading killer among all infectious diseases worldwide despite extensive use of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.